Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies

Table 1 Baseline characteristics

	Dose escalation (n = 26)	GIST expansion (n = 9)
Age	53.3 years (range: 23–71)	61.6 years (range 45–75)
Sex
Female	10 (38.5%)	2 (22.2%)
Male	16 (61.5%)	7 (77.8%)
ECOG PS
0	4	0
1	19	9
2	3	0
Malignancy
Melanoma	8	0
RCC (clear cell)	5	0
NSCLC	3	0
GIST	3	9
Other	7^a	0
Prior treatment regimens (avg, range)	4 (0–11)	4 (1–6)
Prior anti-CTLA4	1	0
Prior imatinib	3	9
Prior regorafenib^b	--	8
Prior sunitinib^b	--	7
Prior nilotinib^b	--	3
Prior sorafenib^b	--	1
Molecular profile
KIT	8	9
Exon 5	1	0
Exon 9	1^c	0
Exon 10	4	0
Exon 11	2	8^c
Exon 13	0	2^c
Exon 17	1^c	2^c
NRAS	3	1
TP53	3	0
KDR	2	0
MET	2	0
PIK3CA	2	0
KRAS	1	0

ECOG PS Eastern cooperative group performance status, GIST gastrointestinal stromal tumor, RCC renal cell carcinoma, NSCLC non-small cell lung cancer
^aProstate, Mesothelioma, Osteosarcoma, Germ-cell tumor, Salivary duct, Renal medullary, Anal
^bPrior TKI exposure reported for GIST expansion only
^cRepresent patients with co-mutations